Ann Dermatol.  2019 Apr;31(2):240-241. 10.5021/ad.2019.31.2.240.

Docetaxel-Aggravated Psoriasis

• Yang S
• Kim BR
• Choi CW
• Youn SW

• KMID: 2439078
• DOI: http://doi.org/10.5021/ad.2019.31.2.240

Abstract

No abstract available.

MeSH Terms

Psoriasis*

Figure

• 

  Fig. 1 Scaly erythematous plaques that appeared 3 days after the administration of docetaxel. We received the patient's consent form about publishing all photographic materials.

Reference

1. Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016; 26:427–443.

2. Allende I, González-Hermosa R, Lázaro M, Díaz-Pérez JL. Psoriasis inducida por docetaxel [Docetaxel-induced psoriasis]. Actas Dermosifiliogr. 2009; 100:629–630. Spanish.

3. Kerob D, Le Maignan C, Vignon-Pennamen MD, Lebbe C. Psoriasis induit par le docétaxel [Docetaxel-induced psoriasis]. Ann Dermatol Venereol. 2010; 137:738–740. French.

4. Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer. 2013; 21:2679–2686.

5. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16:4583–4594.